Licenses cantharidin medicines for Japanese partners and sells YCANTH through wholesalers to clinics and hospitals, while developing treatments for common warts and skin cancers.
10-K for FY2025, filed Mar 11, 2026On March 17, 2021, we entered into a collaboration and license agreement, or the Torii Agreement, with Torii pursuant to which we granted…View ↗
The Company recognizes revenue from sales of a single product, YCANTH (VP-102) (the "Product") in accordance with ASC Topic 606 – Revenue…View ↗
We are a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin…View ↗
Verrica gets paid for YCANTH when it is delivered to wholesalers and distributors; partners pay license fees up front, milestone payments, for product and service supply, and royalties on licensed-product sales.
10-K for FY2025, filed Mar 11, 2026The Company recognizes revenue from sales of a single product, YCANTH (VP-102) (the "Product") in accordance with ASC Topic 606 – Revenue…View ↗
The Company has generated collaboration revenue through its licensing and collaboration arrangements. The terms of the arrangements…View ↗
Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the…View ↗
Milestone Payments: At the inception of an agreement that includes regulatory or commercial milestone payments, the Company evaluates…View ↗
10-K for FY2025, filed Mar 11, 2026
FY2025 revenue by product or service ↗$35.6M
10-K for FY2025, filed Mar 11, 2026
$35.6M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
10-K for FY2025, filed Mar 11, 2026 |
43%
FY2022: 0.0%
|
Product revenue, net, FY2025
$15.3M Sources
|
Sold outright |
|
License and collaboration revenue
|
57% |
License and collaboration revenue, FY2025
$20.3M Sources
|
Verrica sells YCANTH to pharmaceutical wholesalers and distributors, which supply clinics, hospitals and federal healthcare programs. Physicians obtain it through retail or specialty pharmacies or through distribution partners on a buy-and-bill basis.
10-K for FY2025, filed Mar 11, 2026
No. It lost $17.9M in FY2025.
10-Q for Q3 FY2026, filed Nov 13, 2026
−$12.4MView ↗
10-Q for Q3 FY2026, filed Nov 13, 2026
Open tableView ↗
8-K, filed Nov 12, 2026
On July 21, 2026, the Company announced an exclusive distribution, marketing and supply agreement with Medomie Pharma Ltd. regarding…View ↗
Growing. Revenue grew 3.0x in 4 years, from $12M in FY2021 to $35.6M in FY2025, about 31% a year.
From pipeline to commercialization
Earlier, the company described a pipeline spanning molluscum, external and common warts, plantar warts, and skin cancer. The latest report centers on commercializing YCANTH for molluscum and advancing common-wart and skin-cancer treatments.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 11, 2026We are a dermatology therapeutics company developing medications for skin diseases requiring medical intervention. We are primarily focused…View ↗
In addition, we are also developing VP-102 for the treatment of external genital warts, or EGW. EGW is a viral skin disease caused by the…View ↗
VP-102 - Treatment of Common WartsView ↗
VP-103 - Treatment of Plantar WartsView ↗
Loading...